DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Clodronic acid
Clodronic acid
Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
Protocol Supplementary
Date Database Search Strategy Filters Results Results After Duplicates
Phvwp Class Review Bisphosphonates and Osteonecrosis of the Jaw (Alendronic Acid, Clodronic Acid, Etidronic Acid, Ibandronic
June 2011 Circular No
Bone Protection in Myeloma
Annexes to the Annual Report of the European Medicines Agency 2014
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Zoledronic Acid Impairs Stromal Reactivity by Inhibiting M2-Macrophages Polarization and Prostate Cancer-Associated Fibroblasts
Bisphosphonates for Postmenopausal Osteoporosis
Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
Inhibiting the Osteocyte Specific Protein Sclerostin Increases Bone Mass and Fracture Resistance in Multiple Myeloma
Raloxifene Or Calcitonin
Estonian Statistics on Medicines 2013 1/44
Stembook 2018.Pdf
Journal of Population Therapeutics & Clinical Pharmacology
Zoledronic Acid- Reclast and Zometa AHM
WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
Top View
Bisphosphonates and Osteonecrosis of the Jaw: Update on Risk Minimisation Including New Recommendations on Preventative Dental Measures
Assessment Report for Bisphosphonates Containing Medicinal Products
International Comparison of Medicines Usage: Quantitative Analysis
EMEA: CHMP Assessment Report on Bisphosphonates and Osteonecrosis of The
Use of Drugs Against Osteoporosis in the Baltic Countries During 2010
Bone Metabolism Research Reagents Bisphosphonates (Bone Resorption Inhibitors) Non-Nitrogen-Containing Bisphosphonates
Can Bisphosphonates Prevent Recurrent Fragility Fractures? a Systematic Review and Meta-Analysis of Randomized Controlled Trials
6.6.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
Del. 1.B Final Protocol of a Signal Strengthening Study
Australian Public Assessment Report for Zoledronic Acid
Changes Highlighted Final Version Date of Issue
Protocol Use of Antidepressants and Risk of Hip/Femur Fracture
Clodronic Acid (In the Form of Disodium Salt) (Equidae)
Myeloma Bone Disease: a Comprehensive Review
Osteoprotective Medication in the Era of Novel Agents: a European Perspective on Values, Risks and Future Solutions Monika Engelhardt,1,2 Georg W
Questions and Answers on the Review of Bisphosphonates and Atypical
Diagnosis and Management of Osteonecrosis of the Jaw: a Systematic Review and International Consensus
Zoledronic Acid 4Mg/5Ml Concentrate Solution for Prevention of Skeletal
The Rationale for the Intra-Articular Administration of Clodronate in Osteoarthritis
Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects
Harmonized Tariff Schedule of the United States (2006) (Rev
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
ICD-10-CM TABLE of DRUGS and CHEMICALS 2020
The RANK Ligand Inhibitor Denosumab As Novel Therapeutic Agent in the Spectrum of Cancer Bone Disease
Guidelines for ATC Classification and DDD Assignment 2021
99Mtc Bisphosphonates
Treatment of Multiple Myeloma-Related Bone Disease: Recommendations from the Bone Working Group of the International Myeloma Working Group
ANNEX 1: Phvwp Assessment Report on Bisphosphonates and Atrial Fibrillation (For Use by Ncas for Interactions with Mahs for Pamidronic Acid, As Needed)
Multiple Myeloma Associated Bone Disease
Bisphosphonate Guidelines for Treatment and Prevention Of
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Guidelines for ATC Classification and DDD Assignment 2013
CYR61/CCN1 Stimulates Proliferation and Differentiation of Osteoblasts in Vitro and Contributes to Bone Remodeling in Vivo in Myeloma Bone Disease
The Effectiveness of Zoledronic Acid and Ibandronic Acid As Therapy for Bone Metastases in Multiple Myeloma: a Systematic Review
( 12 ) United States Patent
PART VI SUMMARY of the RISK MANAGEMENT PLAN (By Medicinal Product)
BISPHOSPHONATE THERAPY Union for International Cancer Control 2016 Review of Cancer Medicines on the WHO List of Essential Medicines
Download Publication
Annex I Summary of Product Characteristics
Identification of Applicable 6-Digit HS Subheadings for Products Covered by the Proposed Uruguay Round Pharmaceutical Agreement
Halofuginone Inhibits TGF-Β/BMP Signaling and in Combination with Zoledronic Acid Enhances Inhibition of Breast Cancer Bone Metastasis
Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
WP2 Framework for Pharmacoepidemiological Studies